Successful treatment of fibrosing cholestatic hepatitis with pegylated interferon, ribavirin and sofosbuvir after a combined kidney-liver transplantation

被引：20

作者：

Delabaudiere, Cyrielle ^{[1
]}

Lavayssiere, Laurence ^{[1
]}

Doerr, Gaelle ^{[1
]}

Muscari, Fabrice ^{[2
,3
]}

Danjoux, Marie ^{[4
]}

Sallusto, Federico ^{[5
]}

Peron, Jean Marie ^{[3
,6
]}

Bureau, Christophe ^{[3
,6
]}

Rostaing, Lionel ^{[1
,3
,7
]}

Izopet, Jacques ^{[3
,7
,8
]}

Kamar, Nassim ^{[1
,3
,7
]}

机构：

[1] CHU Rangueil, Dept Nephrol & Organ Transplantat, F-31059 Toulouse 9, France

[2] Univ Hosp Rangueil, Dept Surg & Liver Transplantat, Toulouse, France

[3] Univ Toulouse 3, F-31062 Toulouse, France

[4] CHU Purpan, Dept Pathol, Toulouse, France

[5] CHU Rangueil, Dept Urol & Kidney Transplantat, F-31059 Toulouse 9, France

[6] CHU Purpan, Dept Hepatol, Federat Digest, Toulouse, France

[7] CHU Purpan, IFR BMT, INSERM, U1043, Toulouse, France

[8] CHU Purpan, Virol Lab, Toulouse, France

来源：

TRANSPLANT INTERNATIONAL | 2015年 / 28卷 / 02期

关键词：

fibrosing cholestatic hepatitis; hepatitis C virus; kidney transplantation; liver transplantation; sofosbuvir; RECIPIENTS; THERAPY; PEGINTERFERON; INFECTION; ALPHA;

D O I：

10.1111/tri.12428

中图分类号：

R61 [外科手术学];

学科分类号：

摘要：

Fibrosing cholestatic hepatitis (FCH) is a classical but rare and severe form of recurrent hepatitis C virus (HCV) after liver transplantation. Classical anti-HCV therapy, that is pegylated-interferon (peg-interferon) and ribavirin, has been shown to have limited efficacy in treating FCH. Herein, we report on the first case of successful use of peg-interferon, ribavirin, plus sofosbuvir to treat HCV-induced FCH in a combined liver-kidney transplant patient. Antiviral therapy was given for 24 weeks. HCV clearance occurred within 4 weeks after starting therapy and was maintained until 4 weeks after the end of therapy. Antiviral tolerance was good. We conclude that the use of sofosbuvir-based anti-HCV therapy can be successfully used to treat FCH after a liver or combined kidney-liver transplantation.

引用

页码：255 / 258

页数：4

共 50 条

[41] Antiviral maintenance treatment with interferon and ribavirin for recurrent hepatitis C after liver transplantation: Pilot study
Kornberg, Arno
Kuepper, Bernadett
Tannapfel, Andrea
Baerthel, Erik
Thrum, Katharina
Settmacher, Utz
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2007, 22 (12) : 2135 - 2142
[42] Removal from liver transplantation list of a hepatitis C virus-HIV co-infected patient after successful treatment with sofosbuvir and daclatasvir
Llaneras, J.
Castells, L.
Santos, B.
Crespo, M.
Puig, T.
Esteban, J. I.
Esteban, R.
TRANSPLANT INFECTIOUS DISEASE, 2016, 18 (03) : 442 - 445
[43] Combination of sofosbuvir, pegylated-interferon and ribavirin for treatment of hepatitis C virus genotype 1 infection: a systematic review and meta-analysis
Dolatimehr, Fardin
Karimi-Sari, Hamidreza
Rezaee-Zavareh, Mohammad Saeid
Alavian, Seyed Moayed
Behnava, Bita
Gholami-Fesharaki, Mohammad
Sharafi, Heidar
DARU-JOURNAL OF PHARMACEUTICAL SCIENCES, 2017, 25
[44] Pegylated interferon α-2b plus ribavirin in the treatment of post-liver transplant recurrent hepatitis C
Ross, AS
Bhan, AK
Pascual, M
Thiim, M
Cosimi, AB
Chung, RT
CLINICAL TRANSPLANTATION, 2004, 18 (02) : 166 - 173
[45] Efficacy and Tolerability of Pegylated Interferon and Ribavirin in Combination with Simeprevir to Treat Hepatitis C Virus Infections After Living Donor Liver Transplantation
Miuma, Satoshi
Ichikawa, Tatsuki
Miyaaki, Hisamitsu
Haraguchi, Masafumi
Tamada, Yoko
Shibata, Hidetaka
Taura, Naota
Soyama, Akihiko
Hidaka, Masaaki
Takatsuki, Mitsuhisa
Eguchi, Susumu
Nakao, Kazuhiko
JOURNAL OF INTERFERON AND CYTOKINE RESEARCH, 2016, 36 (06) : 358 - 366
[46] Fibrosing Cholestatic Hepatitis in a Complicated Case of an Adult Recipient After Liver Transplantation: Diagnostic Findings and Therapeutic Dilemma
Hori, Tomohide
Onishi, Yasuharu
Kamei, Hideya
Kurata, Nobuhiko
Ishigami, Masatoshi
Ishizu, Yoji
Ogura, Yasuhiro
AMERICAN JOURNAL OF CASE REPORTS, 2016, 17 : 597 - 604
[47] Case report of successful peginterferon, ribavirin, and daclatasvir therapy for recurrent cholestatic hepatitis C after liver retransplantation
Fontana, Robert J.
Hughes, Eric A.
Appelman, Henry
Hindes, Robert
Dimitrova, Dessislava
Bifano, Marc
LIVER TRANSPLANTATION, 2012, 18 (09) : 1053 - 1059
[48] Peg-IFN and ribavirin treatment for recurrence of genotype 2 and 3 hepatitis C after liver transplantation
Ackefors, Malin
Castedal, Maria
Dahlgard, Olav
Verbaan, Hans
Gjertsen, Henrik
Wernerson, Annika
Weiland, Ola
INFECTIOUS DISEASES, 2015, 47 (04) : 209 - 217
[49] Combination therapy with silibinin, pegylated interferon and ribavirin in a patient with hepatitis C virus genotype 3 reinfection after liver transplantation: A case report
Knapstein J.
Wörns M.A.
Galle P.R.
Zimmermann T.
Journal of Medical Case Reports, 8 (1)
[50] Sofosbuvir and simeprevir without ribavirin effectively treat hepatitis C virus genotype 1 infection after liver transplantation in a two-center experience
Jackson, Whitney E.
Hanouneh, Mohamad
Apfel, Tehilla
Alkhouri, Naim
John, Binu V.
Zervos, Xaralambos
Zein, Nizar N.
Hanouneh, Ibrahim A.
CLINICAL TRANSPLANTATION, 2016, 30 (06) : 709 - 713

← 1 2 3 4 5 →